168 related articles for article (PubMed ID: 32912894)
1. Angioedema, ACE inhibitor and COVID-19.
Grewal E; Sutarjono B; Mohammed I
BMJ Case Rep; 2020 Sep; 13(9):. PubMed ID: 32912894
[TBL] [Abstract][Full Text] [Related]
2. A consensus statement on the use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in relation to COVID-19 (corona virus disease 2019).
Talreja H; Tan J; Dawes M; Supershad S; Rabindranath K; Fisher J; Valappil S; van der Merwe V; Wong L; van der Merwe W; Paton J
N Z Med J; 2020 Apr; 133(1512):85-87. PubMed ID: 32242182
[TBL] [Abstract][Full Text] [Related]
3. Do ACE inhibitors and angiotensin receptor antagonists increase the risk of severe COVID-19?
Aamodt AH; Bjørk MH; Tronvik EA; Buanes EA; Stovner LJ; Atar D
Tidsskr Nor Laegeforen; 2020 Jun; 140(9):. PubMed ID: 32549022
[No Abstract] [Full Text] [Related]
4. Continue ACE inhibitors / ARB'S till further evidence in coronavirus disease 2019 (COVID-19).
Bansal S; Agstam S; Gupta A; Gupta P; Isser HS
Indian Heart J; 2020; 72(3):212-213. PubMed ID: 32405087
[No Abstract] [Full Text] [Related]
5. Coronavirus SARS-Cov-2 and arterial hypertension - facts and myths.
Surma S; Romańczyk M; Łabuzek K
Pol Merkur Lekarski; 2020 Jun; 48(285):195-198. PubMed ID: 32564046
[TBL] [Abstract][Full Text] [Related]
6. [ACE-inhibitors, angiotensin receptor blockers and severe acute respiratory syndrome caused by coronavirus].
Verdecchia P; Reboldi G; Cavallini C; Mazzotta G; Angeli F
G Ital Cardiol (Rome); 2020 May; 21(5):321-327. PubMed ID: 32310915
[TBL] [Abstract][Full Text] [Related]
7. Facts and reflections on COVID-19 and anti-hypertensives drugs.
Marin GH
Drug Discov Ther; 2020 May; 14(2):105-106. PubMed ID: 32213760
[TBL] [Abstract][Full Text] [Related]
8. Covid-19: the renin-angiotensin system imbalance hypothesis.
Lanza K; Perez LG; Costa LB; Cordeiro TM; Palmeira VA; Ribeiro VT; Simões E Silva AC
Clin Sci (Lond); 2020 Jun; 134(11):1259-1264. PubMed ID: 32507883
[TBL] [Abstract][Full Text] [Related]
9. [Drugs that aggravate the course of COVID-19 : really ?].
Rothuizen LE; Livio F; Buclin T
Rev Med Suisse; 2020 Apr; 16(N° 691-2):852-854. PubMed ID: 32348052
[TBL] [Abstract][Full Text] [Related]
10. Comparative Impacts of ACE (Angiotensin-Converting Enzyme) Inhibitors Versus Angiotensin II Receptor Blockers on the Risk of COVID-19 Mortality.
Zhou F; Liu YM; Xie J; Li H; Lei F; Yang H; Qin JJ; Cai J; Zhang XJ; Wu B; Xia M; Xiang D; Yang C; Ma X; Xu Q; Lu Z; Lu H; Xia X; Wang D; Liao X; Peng G; Yang J; Huang X; Zhang BH; Yuan Y; Wei X; Liu PP; Wang Y; Zhang P; She ZG; Xia J; Li H
Hypertension; 2020 Aug; 76(2):e15-e17. PubMed ID: 32493070
[No Abstract] [Full Text] [Related]
11. Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study.
Yang G; Tan Z; Zhou L; Yang M; Peng L; Liu J; Cai J; Yang R; Han J; Huang Y; He S
Hypertension; 2020 Jul; 76(1):51-58. PubMed ID: 32348166
[TBL] [Abstract][Full Text] [Related]
12. Coronavirus disease 2019 (COVID-19): angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and cardiovascular disease.
Jennings GL
Med J Aust; 2020 Jun; 212(11):502-503.e1. PubMed ID: 32441063
[No Abstract] [Full Text] [Related]
13. A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19.
Wang Z; Zhang D; Wang S; Jin Y; Huan J; Wu Y; Xia C; Li Z; Qi X; Zhang D; Han X; Zhu X; Qu Y; Wang Q
Med Sci Monit; 2020 Sep; 26():e926651. PubMed ID: 32969367
[TBL] [Abstract][Full Text] [Related]
14. Related molecular mechanisms of COVID-19, hypertension, and diabetes.
Akkus E; Sahin M
Am J Physiol Endocrinol Metab; 2020 Jun; 318(6):E881. PubMed ID: 32479159
[No Abstract] [Full Text] [Related]
15. Renin-angiotensin system inhibitors in management of hypertension during the COVID-19 pandemic.
Dworakowska D; Grossman AB
J Physiol Pharmacol; 2020 Apr; 71(2):. PubMed ID: 32633235
[TBL] [Abstract][Full Text] [Related]
16. Angioedema in COVID-19.
Cohen AJ; DiFrancesco MF; Solomon SD; Vaduganathan M
Eur Heart J; 2020 Sep; 41(34):3283-3284. PubMed ID: 32441750
[No Abstract] [Full Text] [Related]
17. Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome.
van de Veerdonk FL; Netea MG; van Deuren M; van der Meer JW; de Mast Q; Brüggemann RJ; van der Hoeven H
Elife; 2020 Apr; 9():. PubMed ID: 32338605
[TBL] [Abstract][Full Text] [Related]
18. [Hypertension, RAAS blockade and risk in COVID-19 patients].
Spaak J; Kahan T
Lakartidningen; 2020 Jun; 117():. PubMed ID: 32594472
[TBL] [Abstract][Full Text] [Related]
19. Reply: ACE Inhibitors and Angiotensin II Receptor Blockers May Have Different Impact on Prognosis of COVID-19.
Amat-Santos IJ; Santos-Martinez S; López-Otero D; Delgado-Arana JR; San Román JA
J Am Coll Cardiol; 2020 Oct; 76(17):2042. PubMed ID: 33092743
[No Abstract] [Full Text] [Related]
20. ACE Inhibitors and Angiotensin II Receptor Blockers May Have Different Impact on Prognosis of COVID-19.
Wang Y; Tse G; Li G; Lip GYH; Liu T
J Am Coll Cardiol; 2020 Oct; 76(17):2041. PubMed ID: 33092742
[No Abstract] [Full Text] [Related]
[Next] [New Search]
